Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q2 2026 › vs Q2 2025
Teva Pharmaceutical Industries (TEVA) Q2 2026 vs Q2 2025 (year over year)
Teva Pharmaceutical Industries's revenue fell $34.0M (-0.8%) from $4.2B in Q2 2025 to $4.1B in Q2 2026. The biggest changes: Distribution Service +$56.0M (+15%); Product and Service Other −$47.0M (-40%); Product −$34.0M (-0.9%).
Teva Pharmaceutical Industries, Q2 2026: revenue $4.1B (-0.8% year over year), operating margin -5.6%, net loss $575M, operating cash flow $411M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.4% | 3.1% | +4.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $3.6B | $3.6B | −$34.0M | -0.9% |
| Distribution Service | $433M | $377M | $56.0M | +15% |
| Product and Service Other | $70.0M | $117M | −$47.0M | -40% |
| License | $37.0M | $46.0M | −$9.0M | -20% |
| Revenue | $4.1B | $4.2B | −$34.0M | -0.8% |
| Net loss | $575M | −$283M | $858M | — |
| Costs & expenses | $4.7B | $4.3B | $463M | +11% |
| Operating costs | $4.4B | $3.7B | $652M | +18% |
| Interest & other, net | $224M | $250M | −$26.0M | -10% |
| Income tax | $121M | −$78.0M | $199M | — |
| Cost of revenue | $2.0B | $2.1B | −$85.0M | -4% |
| Research & development | $970M | $244M | $726M | +298% |
| Sales & marketing | $717M | $654M | $63.0M | +10% |
| General & admin | $317M | $305M | $12.0M | +4% |
| Other operating costs | $380M | $444M | −$64.0M | -14% |
| Operating cash sources | $986M | −$56.0M | $1.0B | — |
| Depreciation & amortization | $241M | $251M | −$10.0M | -4% |
| Share-based compensation | $40.0M | $38.0M | $2.0M | +5% |
| Working capital & other | $705M | −$345M | $1.1B | — |
| Net loss absorbed | $575M | −$283M | $858M | — |
| Operating cash flow | $411M | $227M | $184M | +81% |
| Free cash flow (OCF − capex) | $307M | $131M | $176M | +134% |
| Capital expenditures | $104M | $96.0M | $8.0M | +8% |
Questions
How much did Teva Pharmaceutical Industries's revenue grow year over year in Q2 2026?
Teva Pharmaceutical Industries's revenue fell $34.0M (-0.8%) from $4.2B in Q2 2025 to $4.1B in Q2 2026.
What drove Teva Pharmaceutical Industries's revenue change in Q2 2026?
Distribution Service +$56.0M (+15%); Product and Service Other −$47.0M (-40%); Product −$34.0M (-0.9%).